POM-V Prescription Required Companion Animal

Arixil Vet 5 mg Film-coated Tablet for Dogs and Cats

Active ingredient: Benazepril Hydrochloride

Form

Tablet

Species

Cats Dogs

Manufacturer

Industrial Veterinaria SA

VMD MA No.

36547/4007

What it's used for

DOGS: Treatment of congestive heart failure. CATS: Reduction of proteinuria associated with chronic kidney disease.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Benazepril Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Arixil Vet 5 mg Film-coated Tablet for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

DOGS: Treatment of congestive heart failure.
CATS: Reduction of proteinuria associated with chronic kidney disease.

For oral use.
In dogs:
It should be given orally once daily, with or without food. The dose is 0.23 mg
benazepril /kg bw per day, corresponding to 0.25 mg of Benazepril hydrochloride / kg
bw per day, according to the following table:
Weight of dog (kg) Number of tablets > 5 - 100.5 > 10 - 201
The dose may be doubled, still administered once daily, if judged clinically necessary
and advised by the veterinary surgeon.
In cats:
It should be given orally once daily, with or without food. The dose is 0.46 mg
benazepril /kg bw per day, corresponding to 0.50 mg of Benazepril hydrochloride / kg
bw per day, according to the following table:
Weight of cat (kg)Number of tablets2.5 – 5.00.5 5.1 – 10.01

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases of cardiac output failure, due to aortic or pulmonary stenosis.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal
failure.
Do not use during pregnancy or lactation (see section 4.7).

In double-blind clinical trials in dogs with congestive heart failure, the veterinary
medicinal product was well tolerated with an incidence of adverse reactions lower than
observed in placebo treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of
fatigue.
In cats and dogs with chronic kidney disease, the veterinary medicinal product may
increase plasma creatinine concentrations at the start of therapy. A moderate increase
in plasma creatinine concentrations following administration of ACE inhibitors is
compatible with the reduction in glomerular hypertension induced by these agents, and
is therefore not necessarily a reason to stop therapy in the absence of other signs.
The veterinary medicinal product may increase food consumption and body weight in
cats.
Emesis, anorexia, dehydration, lethargy and diarrhea have been reported in rare
occasions in cats.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Unlimited Renewal: May 2024
AN: 03944/2023

None

Special precautions for use in animals
No evidence of renal toxicity to the veterinary medicinal product has been observed
in dogs or cats during clinical trials, however, as is routine in cases of chronic kidney
disease, it is recommended to monitor plasma creatinine, urea and erythrocyte
counts during therapy.
The efficacy and safety of the veterinary medicinal product has not been established
in dogs and cats below 2.5 kg body weight.

Unlimited Renewal: May 2024
AN: 03944/2023
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
•
because angiotensin converting enzyme (ACE) inhibitors have been found to
affect the unborn child during pregnancy in humans.
•
•
the label or the package leaflet to the physician.

Do not store above 25°C.
Store in the outer carton in order to protect from light.
Store in a dry place.
Return any halved tablet to the blister pack and use within 1 day. The blister pack
should be inserted back into the cardboard box.

Unlimited Renewal: May 2024
AN: 03944/2023

The veterinary medicinal product reduced erythrocyte counts in normal cats when
dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when
dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not
observed at the recommended dose during clinical trials in cats or dogs.
Transient reversible hypotension may occur in cases of accidental overdose.
Therapy should consist of intravenous infusion of warm isotonic saline.
4.11 Withdrawal period:
Not applicable

Unlimited Renewal: May 2024
AN: 03944/2023
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.